Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 2276 · Eliminating Thickets to Increase Competition Act ·

ETHIC Act

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

35 U.S.C. § 271 Infringement of patent

+32 −0Shown
More for 35 U.S.C. § 271
Read § 271Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 271(e) of title 35, United States Code, is amended by adding at the end the following:(7) (A) A person who brings an action for infringement of a patent under this section against a party described in subparagraph (B) may assert in the action not more than one patent per Patent Group. (B) A party described in this subparagraph is— (i) a person who— (I) submits an …

§ 271(e)–(f)

Start of § 271 to (e)(6)(A)(ii)(II) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(e)(6)(B)(B) (B)
In an action for infringement of a patent described in subparagraph (A), the sole and exclusive remedy that may be granted by a court, upon a finding that the making, using, offering to sell, selling, or importation into the United States of the biological product that is the subject of the action infringed the patent, shall be a reasonable royalty.In an action for infringement of a patent described in subparagraph (A), the sole and exclusive remedy that may be granted by a court, upon a finding that the making, using, offering to sell, selling, or importation into the United States of the biological product that is the subject of the action infringed the patent, shall be a reasonable royalty.
(e)(6)(C)(C) (C)
The owner of a patent that should have been included in the list described in section 351(l)(3)(A) of the Public Health Service Act, including as provided under section 351(l)(7) of such Act for a biological product, but was not timely included in such list, may not bring an action under this section for infringement of the patent with respect to the biological product.The owner of a patent that should have been included in the list described in section 351(l)(3)(A) of the Public Health Service Act, including as provided under section 351(l)(7) of such Act for a biological product, but was not timely included in such list, may not bring an action under this section for infringement of the patent with respect to the biological product.
(e)(7)(7) [inserted: ]
(e)(7)(A)(A) [inserted: ]
[inserted: A person who brings an action for infringement of a patent under this section against a party described in subparagraph (B) may assert in the action not more than one patent per Patent Group.]
(e)(7)(B)(B) [inserted: ]
[inserted: A party described in this subparagraph is—]
(e)(7)(B)(i)(i) [inserted: ]
[inserted: a person who—]
(e)(7)(B)(i)(I)(I) [inserted: ]
[inserted: submits an application for approval of a drug under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), or is a holder of such an approved application; or]
(e)(7)(B)(i)(II)(II) [inserted: ]
[inserted: submits an application for licensure of a biological product under section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)), or is a holder of such a licensure; or]
(e)(7)(B)(ii)(ii) [inserted: ]
[inserted: a person making, using, selling, offering for sale, introducing or delivering into interstate commerce, or importing—]
(e)(7)(B)(ii)(I)(I) [inserted: ]
[inserted: a drug approved pursuant to an application under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355); or]
(e)(7)(B)(ii)(II)(II) [inserted: ]
[inserted: a biological product licensed under section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)).]
(e)(7)(C)(C) [inserted: ]
[inserted: A person who brings an action described in subparagraph (A) asserting a patent against a party may not bring any additional actions described in that subparagraph asserting a patent in the same Patent Group against that party.]
(e)(7)(D)(D) [inserted: ]
(e)(7)(D)(i)(i) [inserted: ]
[inserted: For purposes of this paragraph, the term “Patent Group” means 2 or more commonly owned patents or applications that—]
(e)(7)(D)(i)(I)(I) [inserted: ]
[inserted: are identified on 1 or more disclaimers under section 253 to obviate obviousness-type double patenting of another commonly owned patent; or]
(e)(7)(D)(i)(II)(II) [inserted: ]
[inserted: are subject to 1 or more disclaimers under section 253 to obviate obviousness-type double patenting of another commonly owned patent.]
(e)(7)(D)(ii)(ii) [inserted: ]
[inserted: For purposes of clause (i)(I)—]
(e)(7)(D)(ii)(I)(I) [inserted: ]
[inserted: each patent or application that identifies the same patent or application on a disclaimer under section 253 is part of the same Patent Group; and]
(e)(7)(D)(ii)(II)(II) [inserted: ]
[inserted: each patent or application that is identified on a disclaimer under section 253 is part of the same Patent Group as the patent or application subject to the disclaimer.]
(f)(f) (f)
(f)(1)(1) (1)
Whoever without authority supplies or causes to be supplied in or from the United States all or a substantial portion of the components of a patented invention, where such components are uncombined in whole or in part, in such manner as to actively induce the combination of such components outside of the United States in a manner that would infringe the patent if such combination occurred within the United States, shall be liable as an infringer.Whoever without authority supplies or causes to be supplied in or from the United States all or a substantial portion of the components of a patented invention, where such components are uncombined in whole or in part, in such manner as to actively induce the combination of such components outside of the United States in a manner that would infringe the patent if such combination occurred within the United States, shall be liable as an infringer.

Rest of § 271 unchanged

Step through the changes